Side-by-side · Research reference
KPVvsMOTS-c
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft13/39 cited
BAnimal-StrongReviewed16/68 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
01Mechanism of Action
Parameter
KPV
MOTS-c
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Feedback intact?
No melanocortin receptor binding
Stress-responsive, AMPK-dependent nuclear translocationKim 2018
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
MOTS-c
Standard dose
200–500 mcg / day SQ or oralDalle-Pang 2024
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
Frequency
Daily or 2–3× per week
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Lower / starter dose
100 mcg / day
2.5–5 mg / week
Recommended due to limited human data.
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Duration
4–8 weeks per cycle
4–12 weeks (experimental)
Optimal cycle length unknown.
Reconstitution
Bacteriostatic water (SQ form)
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
Timing
No specific time; often taken with / before meals (oral)
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
Half-life
Hours (estimated; rapid tissue uptake)
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
03Metabolic / Fat Loss Evidence
Parameter
KPV
MOTS-c
Primary fat target
—
Diet-induced / metabolic obesity; systemic fat utilization
Quantified reduction
—
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
IGF-1 impact
—
No direct IGF-1 pathway; AMPK-mediated
Effect on lean mass
—
High dose significantly ↑ lean mass in mice
Triglycerides
—
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
Effect reversibility
—
Unknown — no long-term follow-up data
Key publication
—
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
04Side Effects & Safety
Parameter
KPV
MOTS-c
Injection site reaction
Mild irritation
Mild irritation (reported)
GI symptoms
Rare nausea (oral form)
Nausea, stomach discomfort (reported)
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
Avoid — insufficient safety data
Fluid retention / Edema
—
Not reported
Cardiovascular
—
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
Cancer risk
—
Contradictory data — some models suggest pro-proliferative effects
CNS / Neurological
—
Insomnia, headache (anecdotal reports)
Antibody formation
—
No data (no long-term human trials)
Evidence quality
—
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
05Administration Protocol
Parameter
KPV
MOTS-c
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
3. Timing
Morning preferred; oral form taken with / before meals.
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
5. Needle
29–31G insulin syringe (SQ form).
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction